ESSA Pharma Inc. (EPIX) Upgraded by Zacks Investment Research to “Buy”
Zacks Investment Research upgraded shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) from a hold rating to a buy rating in a research note published on Monday morning. The brokerage currently has $0.50 price target on the stock.
According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “
EPIX has been the topic of several other reports. ValuEngine downgraded shares of ESSA Pharma from a sell rating to a strong sell rating in a research note on Wednesday, June 7th. Dawson James reaffirmed a buy rating on shares of ESSA Pharma in a research note on Thursday, August 3rd. Finally, Bloom Burton reaffirmed a buy rating on shares of ESSA Pharma in a research note on Thursday, May 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. ESSA Pharma has a consensus rating of Buy and a consensus target price of $4.75.
ESSA Pharma (EPIX) remained flat at $0.31 during midday trading on Monday. 9,724 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $0.35 and its 200 day moving average price is $1.43. ESSA Pharma has a 12 month low of $0.25 and a 12 month high of $3.59. The company’s market cap is $9.02 million.
WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/12/essa-pharma-inc-epix-upgraded-by-zacks-investment-research-to-buy.html.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Receive News & Stock Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related stocks with our FREE daily email newsletter.